Navigation Links
Sorrento Therapeutics Announces Pricing of Public Offering of 4,150,000 Shares of Common Stock and Listing on NASDAQ
Date:10/24/2013

apital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc. is a publicly-traded, development-stage biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs. Sorrento's therapeutic focus is oncology, but is also developing therapeutic products for inflammation, metabolic, and infectious diseases, as well as for the treatment of chronic pain. Sorrento's proprietary G-MAB® fully-human antibody library platform was designed to facilitate the rapid identification and isolation of highly specific antibody therapeutics. In addition, Sorrento is developing proprietary Antibody Drug Conjugates as well as Antibody formulated Drug Conjugates combining its G-MAB® antibodies with anti-tumor agents.

More information is available at www.sorrentotherapeutics.com.

Forward-Looking Statements
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Words such as "assumes," "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements. Forward-looking statements include statements about the preclinical and clinical development of Sorrento's human antibody therapeutics. All such forward-looking statements are based on Sor
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sorrento Therapeutics Secures Rights to Biomiga Diagnostics Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
2. Sorrento Therapeutics Completes IgDraSol Merger
3. Sorrento Therapeutics to Present at Two Healthcare Conferences
4. Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
5. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
6. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
7. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
8. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
9. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
10. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
11. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... WASHINGTON , Sept. 2, 2014 The ... America,s pharmacy benefit managers (PBMs), today filed a lawsuit ... a sweeping new Iowa law ... drug costs for the state,s employers and consumers.  ... generic drugs by severely restricting the use of Maximum ...
(Date:9/2/2014)... , Sept. 2, 2014 Reportlinker.com ... available in its catalogue: Acute Heart ... http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html Acute ... Summary GlobalData,s clinical trial report, ... 2014" provides data on the Acute Heart Failure ...
(Date:9/2/2014)... Spanje, September 2, 2014 ... AF Registry bij het ESC CONGRESS 2014 ... patiënten met risico op beroerte in de ... Gegevens van bijna 12.500 patiënten ingeschreven in ... Fibrillation (GARFIELD-AF), een innovatief, onafhankelijk initiatief op ...
Breaking Medicine Technology:Lawsuit Challenges Iowa Health Mandate that Forces Employers to Pay More for Prescription Drugs 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 2Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 3Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 4Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 5Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 6Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 7Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 8Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 9Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 10
... BioDelivery Sciences International, Inc. (Nasdaq: BDSI ... 1 study assessing the pharmacokinetics of a BEMA ... commercialize a high dose formulation of buprenorphine combined ... of opioid dependence. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO) ...
... -- Golden Meditech Holdings Limited ("Golden ... 801.HK; 910801.TW), which embodies a leading medical devices enterprise, a ... cell cord blood banking operator in China, is pleased to ... With a track record in China for establishing ...
Cached Medicine Technology:BioDelivery Sciences Announces Positive Results Supporting BEMA Buprenorphine/Naloxone Formulation for Opioid Dependence 2BioDelivery Sciences Announces Positive Results Supporting BEMA Buprenorphine/Naloxone Formulation for Opioid Dependence 3BioDelivery Sciences Announces Positive Results Supporting BEMA Buprenorphine/Naloxone Formulation for Opioid Dependence 4Golden Meditech Celebrates Grand Opening of Taiwan Representative Office 2Golden Meditech Celebrates Grand Opening of Taiwan Representative Office 3
(Date:9/2/2014)... San Diego, CA (PRWEB) September 02, 2014 ... guide titled, “Is Group Therapy Right for Me?” The ... joining group therapy or counseling, in addition to common ... in group therapy improve not only from the interventions ... the group and receiving feedback from group members,” says ...
(Date:9/2/2014)... Atlanta, Ga. (PRWEB) September 02, 2014 ... hosted by, respectively, top-industry professionals Carey Lewis ... each person auditioning, seeking those who have the desire ... chosen for a callback, performers could be invited to ... SHINE convention. , Charlotte, NC – Saturday, Sept. 6, ...
(Date:9/2/2014)... NV (PRWEB) September 02, 2014 Cloud ... provider of “Cloud Based” Medical Practice Business Operations solutions ... provider of Digital Cyber Security solutions for all industries ... interviewed on the trading floor of the CME in ... Mr. DeLaGarza stated that we are very proud of ...
(Date:9/2/2014)... 02, 2014 On August 30, 2014, ... titled “Why You Should Wash Your Face .” ... the global population breathes air considered polluted by the ... lodge in the skin’s pores destroying its natural oils. ... free radicals that may cause cell damage, redness, ...
(Date:9/2/2014)... in California, the percentage undergoing a double mastectomy increased ... not associated with a lower risk of death than ... the September 3 issue of JAMA . The ... one breast was associated with a higher risk of ... , Randomized trials have demonstrated similar survival for patients ...
Breaking Medicine News(10 mins):Health News:Actors, Models and Talent for Christ Auditions Are Set for Charlotte and Omaha on Saturday, September 6, 2014 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 3Health News:Simon Ourian, Kim Kardashian’s Doctor: Air Pollution May Be Aging Your Skin 2Health News:Increase seen in use of double mastectomy 2Health News:Increase seen in use of double mastectomy 3
... unpredictable and often fatal, researchers say, , , THURSDAY, July 31 ... aortic dissection could lead to a rapid diagnostic test for ... dissection is a tear in the lining of the aorta, ... rest of the body. About 2,000 people a year in ...
... While summer is the time of year people like ... many sinus sufferers from enjoying activities such as barbequing, hanging ... to name a few. , In fact, a new ... sinus sufferers say they miss or cut short social outings ...
... thousands of Americans,prepare to attend the upcoming Olympic Games ... -- and how to deal with it -- is,in ... care in foreign lands can be,daunting, but travelers who ... said Angelo Masciantonio, CEO and co-founder of HTH,Worldwide, a ...
... announced that the company will report financial results for,the first ... April 24,2009 on Thursday, August 21, 2008 at 8:00 AM ... results on the same day at 9:00 AM EDT., ... To listen to the conference call live by telephone dial ...
... consumers. , ... Orlando, FL (Vocus) July 31, 2008 ... vendor in its "Hype Cycle for Healthcare Payers, 2008" report. Connextions, ... attract, retain and manage individual and small group members. ...
... Kenneth O.,Klepper, president & chief operating officer, Medco Health ... the BMO Capital Markets 2008 Focus on,Healthcare Conference in ... presentation at the Millennium Broadway Hotel will begin at ... also scheduled to,attend., The presentation may be heard ...
Cached Medicine News:Health News:Gene Test Could Catch Deadly Heart Problem 2Health News:Gene Test Could Catch Deadly Heart Problem 3Health News:Sinus sufferers miss out on work or social activities due to summer allergies 2Health News:Americans Attending Beijing Olympics Should Plan Ahead for Medical Emergencies 2Health News:Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 First Quarter Financial Results 2Health News:Connextions Cited in Leading Industry Analyst Firm's "Hype Cycle" For Health Care Provider Marketing Applications 2Health News:Connextions Cited in Leading Industry Analyst Firm's "Hype Cycle" For Health Care Provider Marketing Applications 3Health News:Medco to Present at the BMO Capital Markets 2008 Focus on Healthcare Conference 2
... HCS INTERACTANT is ... system. Financial applications include ... human resources and comprehensive ... financial applications are designed ...
... is intended for the determination of C-Reactive ... on automated clinical chemistry analyzers. The erCRP ... a high sensitive method to ensure a ... entire measurable range (0.15 320mg/L). The ...
... Infinity Urea single liquid stable reagent ... of single liquid stability to help ... and provide quick result turnaround time. ... Urea reagent provides a long shelf ...
... The Infinity Lithium single liquid stable ... convenience of single liquid stability to ... error and provide quick result turnaround ... Infinity Lithium reagent provides a long ...
Medicine Products: